MedTrace Logo

Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial

NCT03871621 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2023-03-22

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the efficacy of the SGLT2 inhibitor dapagliflozin, as compared with standard care of diabetes, on left ventricular (LV) structural and functional change in asymptomatic type 2 diabetes mellitus (DM) patient.

Conditions

Interventions

DRUG

Diabetes Medicines

Anti-diabetic medications except SGLT2 inhibitors

DRUG

Dapagliflozin

Dapagliflozin tablet (10 mg)

Sponsors & Collaborators

  • Mackay Memorial Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2022-05-01
Completion
2022-08-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03871621 on ClinicalTrials.gov